Focal therapy in localised prostate cancer: real-world urological perspective explored in a cross-sectional European survey

File Description SizeFormat 
Manuscript V1 DEF.docFile embargoed until 06 October 2019161 kBMicrosoft Word    Request a copy
Title: Focal therapy in localised prostate cancer: real-world urological perspective explored in a cross-sectional European survey
Authors: Marra, G
Ploussard, G
Ost, P
De Visschere, PJL
Briganti, A
Gandaglia, G
Tilki, D
Surcel, CI
Tsaur, I
Van Den Bergh, RCN
Kretschmer, A
Borgmann, H
Gontero, P
Ahmed, HU
Valerio, M
EAU-YAU Prostate Cancer Working Party
Item Type: Journal Article
Abstract: INTRODUCTION: The urological community's opinion over focal therapy (FT) for prostate cancer (PCa) has never been assessed. Our aim was to investigate the current opinion on FT in the European urological community. METHODS: A 25-item questionnaire was devised according to the Cherries checklist and distributed through SurveyMonkey using a web link from November 2016 to October 2017. After a pilot validation (n = 40 urologists), the survey was sent through EAU and 9 other national European urological societies mailing list. Twitter was also used. RESULTS: We received 484 replies from 51 countries. Almost half (44.8%, n = 217) stated FT would represent a step forward, and 52.0% (n = 252) would suggest FT to a patient. Almost three-quarters (70.8%, n = 343) agreed FT will become a standard option after improvements in patient selection (n = 66) or when its effectiveness will be proven (n = 78), or both (n = 199). Most frequently used definition of FT was treatment of all significant (life-threatening) cancer foci whilst leaving untreated the rest of the gland (39.3%, n = 190). FT use was considered as an alternative to whole-gland treatments by 29.7% (n = 144), and to AS by 25.0% (n = 121). On multivariate analysis, FT availability and publications were associated with a positive opinion on FT. Conversely, attending International congresses, treating high PCa volumes and high percentages of high-risk PCa was associated with a negative opinion. CONCLUSIONS: FT is considered as an attractive option for PCa treatment by the European urological community sampled by our survey. FT availability positively influences these thoughts. The present survey suggests whilst some early adopters already embraced FT, the relative majority of the urological community is prone to embrace FT in the near future, once current areas of debate are solved.
Issue Date: 1-Dec-2018
Date of Acceptance: 15-Aug-2018
URI: http://hdl.handle.net/10044/1/63533
DOI: https://dx.doi.org/10.1016/j.urolonc.2018.08.013
ISSN: 1078-1439
Publisher: Elsevier
Start Page: 529.e11
End Page: 529.e22
Journal / Book Title: Urologic Oncology: Seminars and Original Investigations
Volume: 36
Issue: 12
Copyright Statement: © 2018 Elsevier Inc. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence http://creativecommons.org/licenses/by-nc-nd/4.0/
Sponsor/Funder: Wellcome Trust
Funder's Grant Number: 204998/Z/16/Z
Keywords: Clinical practice
European Association of Urology
Focal therapy
Prostate cancer
Survey
Young Academic Urologists
EAU-YAU Prostate Cancer Working Party
1112 Oncology And Carcinogenesis
Urology & Nephrology
Publication Status: Published
Conference Place: United States
Embargo Date: 2019-10-06
Online Publication Date: 2018-10-06
Appears in Collections:Division of Surgery
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commonsx